KRAS and colorectal carcinoma: Collectively, these results suggest that heteronemin combined with tetrac inhibited PI3K and ERK1/2 activation in HT-29 cells (KRAS WT CRC) and ERK1/2 in HCT-116 cells (KRAS MT CRC), which correlated with the suppression of EGFR.